Jade Biosciences Inc(JBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.61 | Insider Own | 14.3% | Shs Outstand | 63.6M | Perf Week | -3.63% |
| Market Cap | 0.89B | Forward P/E | - | EPS next Y | 0.95% | Insider Trans | - | Shs Float | 54.5M | Perf Month | 2.11% |
| Enterprise Value | 0.43B | PEG | - | EPS next Q | -0.73 | Inst Own | 104.84% | Short Float | 20.57% | Perf Quarter | -26.58% |
| Income | -0.14B | P/S | - | EPS this Y | 7.46% | Inst Trans | 47.3% | Short Ratio | 12.59 | Perf Half Y | -41.97% |
| Sales | 0.00B | P/B | 2.03 | EPS next 5Y | 3.75% | ROA | -44.03% | Short Interest | 11.21M | Perf YTD | -8.88% |
| Book/sh | 6.92 | P/C | 1.94 | EPS past 3/5Y | 61.94% 21.92% | ROE | -47.78% | 52W High | -49.79% ($28.00) | Perf Year | 42.74% |
| Cash/sh | 7.25 | P/FCF | - | Sales past 3/5Y | - | ROIC | -34.78% | 52W Low | 68.18% ($8.36) | Perf 3Y | -61.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 91.41% | Gross Margin | - | Volatility(W/M) | 4.87% 6.06% | Perf 5Y | -75.86% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.85 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.93 | EPS Q/Q | 33.03% | Profit Margin | - | RSI (14) | 40.44 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.93 | Sales Q/Q | - | SMA20 | -0.75% ($14.17) | Beta | 1.68 | Target Price | $49.89 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/10 | SMA50 | -14.74% ($16.49) | Rel Volume | 0.77 | Prev Close | $14.24 |
| Employees | 55 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -19.42% - | SMA200 | -22.92% ($18.24) | Avg Volume(3M) | 0.89M | Price | $14.06 |
| IPO | 2021/6/30 | Option/Short | Yes/Yes | Trades | 5148 | Volume | 682,077 | Change | -1.26% |
🧬 Jade Biosciences (JBIO) is a U.S. clinical-stage biotech targeting autoimmune and inflammatory diseases. Its lead candidate is a monoclonal antibody that blocks an immune protein called April ligand, currently in Phase 1 clinical trials, and the company also holds an additional preclinical pipeline. It is a drug development-focused company with no product revenue yet.
Over the past 1 year, roughly in the middle
50% below its 1-year high.
Traded less than usual. That is 77% of its average volume.
JBIO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +7.5% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -75.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.6% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #167 of 597 in the industry
Based on market cap of $894M.
MGTX#165 MeiraGTx Holdings plc $911M PER 13.4 
ALMS#166 Alumis Inc $898M PER - JBIO#167 Jade Biosciences Inc $894M PER - 
ANRO#168 Alto Neuroscience Inc $887M PER - 
AKTS#169 Aktis Oncology Inc $886M PER - 
FAQ
What kind of company is JBIO?
JBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of JBIO?
The market cap of JBIO is approximately $894M, ranking 2,664 within its sector.
What is the 52-week high and low for JBIO?
JBIO has recorded a 52-week high of $28.00 and a low of $8.36.
